Study Design: Retrospective cohort study. Objectives: To evaluate the frequency, risk factors, and impact of incidental durotomy on adverse events and outcomes after TLIF with expandable interbody spacers. Methods: We reviewed 433 consecutive patients treated by TLIF using expandable titanium interbody implants (ALTERA®, Globus Medical Inc) on 538 levels between December 2018 and September 2023. Patients with incidental durotomy (ID) and cerebrospinal fluid leakage were compared to patients without ID, focusing on patient-specific and surgery-related factors, adverse events, clinical outcomes (MacNab criteria), and radiological outcomes at discharge, 3, and 12 months. Results: The ID rate was 9.0% (39/433 patients). Patients with ID had lower BMI (26.1 ± 5.2 vs 28.0 ± 5.3 kg/m 2 , P = .03), longer surgery duration (358 ± 132 vs 305 ± 128 minutes, P = .01), and extended hospital stays (14.7 ± 12.8 vs 10.9 ± 8.2 days, P < .01). More postoperative adverse events (51.3% vs 28.7%, P = .004) with higher severity (28.2% vs 13.2% moderate to severe, P = .019) occurred at discharge. No differences were found in outcomes at 3 or 12 months. ID patients showed higher risks for impaired wound healing (adjusted OR, 4.39; 95% CI, 1.90-10.2; P = .001) and pulmonary embolism (adjusted OR, 3.52; 95% CI, 1.13-10.9; P = .029). Conclusions: Incidental durotomy was associated with longer surgery time, hospital stays, and increased early postoperative complications. While not affecting mid-to-long-term outcomes, ID increased risks for wound healing difficulties and pulmonary embolisms.